# A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

> clinical trial · VERIFIED · 2026-06-22

Status: NOT_YET_RECRUITING · Sponsor: Anhui Provincial Cancer Hospital · Condition: Non Small Cell Lung Cancer

- Company: Anhui Provincial Cancer Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07661173

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.